Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Purpose: There has been a recent, rapid increase in prevalence of Methicillin-resistant
Staphylococcus aureus (MRSA) among patients with Cystic Fibrosis (22% across US CF centers in
2009). Some epidemiologic studies suggest possible worse outcomes, a recent analyses showing
this with chronic but not intermittent MRSA. Given the chronic difficult to treat lung
infections in CF it is unclear how the onset of MRSA should be approached. This randomized,
controlled, interventional study seeks to determine if an early eradication protocol is
effective for eradication of MRSA and will provide an opportunity to obtain data regarding
early clinical impact of new isolation of MRSA.
Participants: Cystic fibrosis patients with new isolation of MRSA from their respiratory
culture on a routine clinic visit.
Procedures (methods): Randomized, open-label, multi-center study comparing use of an
eradication protocol to an observational group who receives the current standard of care i.e.
treatment for MRSA only with pulmonary exacerbations.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Baylor College of Medicine CF Therapeutics Development Network Coordinating Center Children's Hospital Medical Center, Cincinnati Cook Children's Medical Center Seattle Children's Hospital St. Louis Children's Hospital University of Alabama at Birmingham University of Colorado, Denver University of Florida University of Michigan University of Texas Southwestern Medical Center University of Washington Washington University School of Medicine